Mike Hollan

Morton discusses his transition from working as a urologist to the C-suite.

Gill discusses her continuing work to transform clinical trials and improve the patient experience through DCTs.

Industry experts discuss the relationship between digital and traditional (key) opinion leaders and how companies are adjusting their strategies to harness the unique brand engagement benefits each role can provide in driving better patient outcomes.

A discussion of the impact the new FDA SaMD guidance, identifying the differences between companion apps and SaMD, and what to expect from this combination in the future.

Klein discusses how recent FDA draft guidelines will impact the use of SaMD in the life sciences industry.

Chandler discusses how life sciences companies are navigating the current climate.

Kirsch discusses the complexity of the drugs and the verification process, along with EVERSANA’s new platform, ACTICS eAccess.

Rubin speaks about how drugs aren’t being properly valued.

Lakdawalla speaks about how drugs aren’t being properly valued.

Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.

Cleve talks about the future of the industry and how data remains a key focus.

Early success ignites promise in reshaping standards of care for HER2 breast cancer.

Embrace the tools that solve real problems and make life easier.

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development.

In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.

The collaboration will use results-based financing to achieve its goals.

The impact on clinical trial staffing would be particularly significant.

The recipe for cross-functional collaboration in drug development. (The story of Justin To, chief operating officer, skeletal dysplasias and gene therapy, for Bridge Bio and a 2023 Emerging Pharma Leader.)

The pluses for pharma are many—alongside experienced workers.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

After the pandemic forced fundamenta­l­­­­ changes in the ways pharma and key opinion leaders worked together, both groups are using what they learned for a more seamless connection.

The importance of not over-expanding during development, launch.

How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?

Chronicling Davidek Herron’s career crossover from playing professional basketball to leading Roche’s digital transformation and scale-up efforts—and the team lessons learned along the way.

Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.

Biopharma insiders believe it’s time to invest in technology again.

As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.

Pharma companies are teaming with academic institutions earlier in the R&D process.

Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.

Companies should search within to gain talent edge.